Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno

Small cell lung cancer (SCLC) is characterized by rapid progression and poor prognosis. Although the phase II CITYSCAPE-02 trial found objective response rate (ORR) and progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients improved when tiragolumab was added to atezolizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Brazel, Danielle, Ou, Sai-Hong Ignatius, Nagasaka, Misako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831070/
https://www.ncbi.nlm.nih.gov/pubmed/36636263
http://dx.doi.org/10.2147/LCTT.S379389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831070/
https://www.ncbi.nlm.nih.gov/pubmed/36636263
http://dx.doi.org/10.2147/LCTT.S379389

Ejemplares similares